What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Articles in this issue
Key Factors Attributing to a Successful Product Launch
Closing the Digital Gap: FDA’s Oversight of Social Media
Sales-Rep Compensation: Adding Long-Term Incentives to Mix
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
Co-creating New Innovations
The Potential Impact of the IRA
Patient Hubs Continue Growth
Social Media’s Complex Climb
Industry Workforce Seeks Clarity
Cybersecurity Threats & Pharma
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Enabling Authenticity
Biopharma Investment Implications: Looking Back and Forward
Payer Key Business Factors for Orphan Product Launches
Innovating the Go-to-Market Model in Asia
Recent Videos
Related Content
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Podcast
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
